


EG-011

Cat. No.:	HY-148683	
CAS No.:	2377113-41-0	
Molecular Formula:	C ₂₈ H ₂₆ N ₄ O ₄	
Molecular Weight:	482.53	
Target:	Arp2/3 Complex	
Pathway:	Cytoskeleton	
Storage:	Powder	-20°C 3 years
	In solvent	-80°C 6 months
		-20°C 1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (259.05 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	Preparing Stock Solutions			1 mg	5 mg
		1 mM		2.0724 mL	10.3621 mL
		5 mM		0.4145 mL	2.0724 mL
10 mM			0.2072 mL	1.0362 mL	
	Please refer to the solubility information to select the appropriate solvent.				
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.31 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (4.31 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (4.31 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	EG-011 is the first-in-class and potent Wiskott-Aldrich syndrome protein (WASP) activator. EG-011 activates the auto-inhibited form of WASP with strong actin polymerization. EG-011 has selective anti-tumor activity in lymphomas ^{[1][2][3]} .
In Vitro	<p>EG-011 (500 nM, 2 μM; 72h) causes a dose-dependent increase in cell death (20-55%) in lymphoma cell lines (OCI-LY-19 and REC1). EG-011 (1, 10 mM; for 24h, 48h) has no cytotoxicity in PBMCs from two healthy donors^[1].</p> <p>EG-011 (500 nM, 5 μM; 24h) causes an increase in actine polymerization in EG-011 sensitive (VL51) and not in resistant (Z138) cell lines at 4, 8 and 24h with both concentrations^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

In Vivo

EG-011 (200 mg/kg; i.p.; 5 days per week) delays tumor growth (Day 6, Day 7, Day 9) and tumor weight in female NOD-SCID mice with the MCL REC-1 cell line. EG-011-treated tumors are 2.2-fold smaller than controls ($P < 0.001$)^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. E. Gaudio, et al. EG-011 IS A NOVEL SMALL MOLECULE WITH IN VITRO AND IN VIVO ANTI-TUMOR ACTIVITY AGAINST LYMPHOMA. Hematological Oncology Volume 37: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano, Switzerland, 18-22 June, 2019.
- [2]. Filippo Spriano, et al. Abstract 1817: EG-011 is a first-in-class Wiskott-Aldrich syndrome protein (WASp) activator with anti-tumor activity. Cancer Res (2022) 82 (12_Supplement): 1817.
- [3]. F. Spriano, et al. The first-in-class WASP activator EG-011 is active in lymphoma and multiple myeloma cell lines resistant to FDA approved compounds. European Journal of Cancer 174S1 (2022) S3-S128.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA